

# Mark R Middleton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7260740/publications.pdf>

Version: 2024-02-01

118  
papers

12,321  
citations

66343

42  
h-index

30922

102  
g-index

125  
all docs

125  
docs citations

125  
times ranked

16647  
citing authors

#	ARTICLE	IF	CITATIONS
1	Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT. <i>Chronic Illness</i> , 2023, 19, 81-94.	1.5	6
2	CGE22-097: Mapping the Mutational Landscape in Patients With Advanced Malignancies Enrolled to Early Phase Clinical Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, CGE22-097.	4.9	0
3	Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 331-338.	6.7	16
4	VCAM-1-targeted MRI Improves Detection of the Tumor-brain Interface. <i>Clinical Cancer Research</i> , 2022, 28, 2385-2396.	7.0	7
5	Lag3: From Bench to Bedside. <i>Cancer Treatment and Research</i> , 2022, 183, 185-199.	0.5	7
6	Abstract 1247: Comprehensive molecular profiling to predict first-line immunochemotherapy outcomes in inoperable esophageal adenocarcinoma. <i>Cancer Research</i> , 2022, 82, 1247-1247.	0.9	0
7	A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and non-small cell lung cancer (NSCLC; IMP-MEL).. <i>Journal of Clinical Oncology</i> , 2022, 40, 2582-2582.	1.6	0
8	Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9553-9553.	1.6	8
9	Abstract CT155: Clinical biomarker studies with an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors indicates potent immune activation. <i>Cancer Research</i> , 2022, 82, CT155-CT155.	0.9	0
10	A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2704-TPS2704.	1.6	0
11	An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2705-TPS2705.	1.6	0
12	ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9609-TPS9609.	1.6	0
13	DETECTION phase II/III trial: Circulating tumor DNA-guided therapy for stage IIB/C melanoma after surgical resection.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9603-TPS9603.	1.6	3
14	Phase I study of the novel pro-drug MIV-818 in patients with hepatocellular carcinoma, intra-hepatic cholangiocarcinoma or liver metastases.. <i>Journal of Clinical Oncology</i> , 2021, 39, 309-309.	1.6	0
15	Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis. <i>BMC Cancer</i> , 2021, 21, 3.	2.6	14
16	Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles. <i>British Journal of Cancer</i> , 2021, 124, 1661-1669.	6.4	20
17	Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 1776.	3.7	24
18	Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study. <i>BMC Cancer</i> , 2021, 21, 642.	2.6	9

#	ARTICLE	IF	CITATIONS
19	Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 125, 510-519.	6.4	59
20	Abstract LB180: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1) Tj ETQq0 0 0 rgBT /Overlock 10 Tf activation. <i>Cancer Research</i> , 2021, 81, LB180-LB180.	0.9	3
21	A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma. <i>BMC Cancer</i> , 2021, 21, 851.	2.6	2
22	Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation. <i>Developmental Cell</i> , 2021, 56, 2808-2825.e10.	7.0	37
23	Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8 <sup>+</sup> T cell clone size and cytotoxicity. <i>Science Immunology</i> , 2021, 6, eabj8825.	11.9	41
24	Interferon-Gamma <sup>+</sup> Producing CD8 <sup>+</sup> Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor <sup>+</sup> Colitis. <i>Gastroenterology</i> , 2021, 161, 1229-1244.e9.	1.3	87
25	Tumour gene expression signature in primary melanoma predicts long-term outcomes. <i>Nature Communications</i> , 2021, 12, 1137.	12.8	33
26	Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. <i>European Journal of Cancer</i> , 2021, 158, 225-233.	2.8	8
27	506...IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors. , 2021, 9, A538-A538.		0
28	Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol. <i>BMJ Open</i> , 2021, 11, e050725.	1.9	21
29	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment “ Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 159-177.	2.8	154
30	Response to: Comment on “Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines”™. <i>European Journal of Cancer</i> , 2020, 140, 154-157.	2.8	1
31	Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives. <i>British Journal of Cancer</i> , 2020, 123, 885-897.	6.4	22
32	sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients. <i>Clinical Cancer Research</i> , 2020, 26, 5709-5719.	7.0	17
33	Adjuvant nivolumab versus ipilimumab in resected stage IIIB <sup>+</sup> C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1465-1477.	10.7	330
34	Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 5869-5878.	7.0	131
35	Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma. <i>European Journal of Cancer</i> , 2020, 132, 176-186.	2.8	15
36	ctDNA monitoring using patient-specific sequencing and integration of variant reads. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	116

#	ARTICLE	IF	CITATIONS
37	Tuning Transcription Factor Availability through Acetylation-Mediated Genomic Redistribution. <i>Molecular Cell</i> , 2020, 79, 472-487.e10.	9.7	38
38	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. <i>European Journal of Cancer</i> , 2020, 128, 60-82.	2.8	131
39	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. <i>European Journal of Cancer</i> , 2020, 128, 83-102.	2.8	181
40	Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma. <i>Nature Medicine</i> , 2020, 26, 193-199.	30.7	211
41	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics “ Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 141-158.	2.8	133
42	Comment on “Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines”™. <i>European Journal of Cancer</i> , 2020, 131, 100-103.	2.8	4
43	A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2).. <i>Journal of Clinical Oncology</i> , 2020, 38, 10022-10022.	1.6	13
44	An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.. <i>Journal of Clinical Oncology</i> , 2020, 38, e22050-e22050.	1.6	14
45	Diagnosis and treatment of basal cell carcinoma: European consensus“based interdisciplinary guidelines. <i>European Journal of Cancer</i> , 2019, 118, 10-34.	2.8	345
46	Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence. <i>European Radiology</i> , 2019, 29, 6717-6727.	4.5	8
47	Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). <i>European Journal of Cancer</i> , 2019, 114, 117-127.	2.8	120
48	Immunotherapy-related hepatitis: real-world experience from a tertiary centre. <i>Frontline Gastroenterology</i> , 2019, 10, 364-371.	1.8	65
49	Immunophenotypes of pancreatic ductal adenocarcinoma: Meta“analysis of transcriptional subtypes. <i>International Journal of Cancer</i> , 2019, 145, 1125-1137.	5.1	30
50	First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. <i>European Journal of Cancer</i> , 2019, 109, 103-110.	2.8	76
51	BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma. <i>Genes and Development</i> , 2019, 33, 310-332.	5.9	35
52	PTU-061“...Immunotherapy-related gastritis in a tertiary oncology centre. , 2019, , .		3
53	Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery. <i>European Radiology</i> , 2019, 29, 2490-2498.	4.5	58
54	Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial. <i>Radiology</i> , 2019, 291, 232-238.	7.3	63

#	ARTICLE	IF	CITATIONS
55	The Circulating Transcriptome as a Source of Biomarkers for Melanoma. <i>Cancers</i> , 2019, 11, 70.	3.7	34
56	VCAM-1-targeted MRI Enables Detection of Brain Micrometastases from Different Primary Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 533-543.	7.0	25
57	A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. <i>Cancer</i> , 2019, 125, 99-108.	4.1	17
58	Alpelisib Plus Fulvestrant in <i>PIK3CA</i> -Altered and <i>PIK3CA</i> -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, e184475.	7.1	187
59	Pharmacodynamic effect of IMCgp100 (TCR-CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9523-9523.	1.6	4
60	Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR-anti-CD3, in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9530-9530.	1.6	3
61	An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9584-9584.	1.6	6
62	A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 406-406.	1.6	8
63	An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2671-TPS2671.	1.6	2
64	Resensitization of uveal melanoma (UM) to immune checkpoint inhibition (ICI) by IMCgp100 (IMC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9592-9592.	1.6	4
65	Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9568-9568.	1.6	0
66	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	10.7	183
67	A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. <i>British Journal of Cancer</i> , 2018, 118, 770-776.	6.4	9
68	Phosphatidylinositol 3-Kinase -Selective Inhibition With Alpelisib (BYL719) in <i>PIK3CA</i> -Altered Solid Tumors: Results From the First-in-Human Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1291-1299.	1.6	298
69	Long-term radiological and histological outcomes following selective internal radiation therapy to liver metastases from breast cancer. <i>Radiology Case Reports</i> , 2018, 13, 1259-1266.	0.6	1
70	Single cell RNA-seq reveals profound transcriptional similarity between Barrett's oesophagus and oesophageal submucosal glands. <i>Nature Communications</i> , 2018, 9, 4261.	12.8	65
71	Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?. <i>Lancet Oncology</i> , The, 2018, 19, 1424-1426.	10.7	1
72	Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals. <i>BMC Health Services Research</i> , 2018, 18, 393.	2.2	15

#	ARTICLE	IF	CITATIONS
73	25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. <i>British Journal of Cancer</i> , 2018, 119, 793-800.	6.4	11
74	Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial. <i>Lancet Oncology</i> , 2018, 19, 1027-1039.	10.7	170
75	Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. <i>Annals of Oncology</i> , 2018, 29, 1843-1852.	1.2	47
76	First-in-class phase I study evaluating MPO250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2520-2520.	1.6	7
77	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9502-9502.	1.6	52
78	Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. <i>Genes and Development</i> , 2017, 31, 18-33.	5.9	184
79	A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2017, 116, 884-892.	6.4	69
80	Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2017, 86, 115-124.	2.8	76
81	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	27.0	1,752
82	Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 266-275.	5.0	27
83	Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox <sup>®</sup> ) using focused ultrasound in patients with liver tumours. <i>Journal of Therapeutic Ultrasound</i> , 2017, 5, 28.	2.2	101
84	Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics. <i>Journal of Thoracic Disease</i> , 2017, 9, 3551-3552.	1.4	0
85	Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9501-9501.	1.6	6
86	Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR. <i>Frontiers in Oncology</i> , 2016, 6, 98.	2.8	34
87	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline " Update 2016. <i>European Journal of Cancer</i> , 2016, 63, 201-217.	2.8	330
88	Restaging oesophageal cancer after neoadjuvant therapy with 18F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery. <i>European Radiology</i> , 2016, 26, 3519-3533.	4.5	27
89	RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases " results and lessons learnt. <i>British Journal of Cancer</i> , 2016, 115, 1193-1200.	6.4	13
90	Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials. <i>Cancer Medicine</i> , 2016, 5, 17-23.	2.8	14

#	ARTICLE	IF	CITATIONS
91	Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the <scp>IMAGE</scp> study. <i>Cancer Medicine</i> , 2016, 5, 1436-1443.	2.8	14
92	Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. <i>Nature Communications</i> , 2016, 7, 11111.	12.8	83
93	Genetic susceptibility to Barrett's oesophagus: Lessons from early studies. <i>United European Gastroenterology Journal</i> , 2016, 4, 485-492.	3.8	5
94	Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report. <i>Targeted Oncology</i> , 2016, 11, 557-563.	3.6	16
95	Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2897-2907.	7.0	48
96	Genetic Biomarkers of Barrett's Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 25-38.	2.3	27
97	Real-world overall survival in advanced melanoma from the IMAGE study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9531-9531.	1.6	0
98	A phase Ib study of NUC1031 and carboplatin for patients with recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5565-5565.	1.6	2
99	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2780-2788.	1.6	1,988
100	Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015, 51, 1989-2007.	2.8	404
101	Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015, 51, 2396-2403.	2.8	320
102	IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide. <i>Oncotarget</i> , 2015, 6, 39877-39890.	1.8	20
103	Dsh Homolog DVL3 Mediates Resistance to IGFIR Inhibition by Regulating IGF-RAS Signaling. <i>Cancer Research</i> , 2014, 74, 5866-5877.	0.9	23
104	Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 262-266.	3.2	36
105	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <i>RAS</i> "RAF" Mutations. <i>Clinical Cancer Research</i> , 2014, 20, 4251-4261.	7.0	60
106	Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence. <i>Journal of Clinical Oncology</i> , 2014, 32, 185-190.	1.6	43
107	Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. <i>Lancet Oncology</i> , The, 2014, 15, 620-630.	10.7	96
108	Safety, pharmacokinetics, and preliminary activity of the $\hat{\pm}$ -specific PI3K inhibitor BYL719: Results from the first-in-human study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2531-2531.	1.6	34



#	ARTICLE	IF	CITATIONS
109	Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.. Journal of Clinical Oncology, 2013, 31, LBA9000-LBA9000.	1.6	5
110	Phase II trial of nemorubicin hydrochloride (N) in combination with cisplatin (cDDP) administered by intra-hepatic artery (IHA) in patients (pts) with hepatocellular carcinoma (HCC): Final results.. Journal of Clinical Oncology, 2013, 31, e15061-e15061.	1.6	0
111	AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence.. Journal of Clinical Oncology, 2013, 31, LBA9000-LBA9000.	1.6	0
112	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine, 2012, 367, 107-114.	27.0	1,976
113	Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. Journal of Experimental Medicine, 2010, 207, 491-503.	8.5	170
114	Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. European Journal of Cancer, 2010, 46, 270-283.	2.8	284
115	Quinone Oxidoreductase-2 Mediated Prodrug Cancer Therapy. Science Translational Medicine, 2010, 2, 40ra50.	12.4	11
116	Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncology, The, 2003, 4, 37-44.	10.7	105
117	Health-Related Quality of Life in Patients with Advanced Metastatic Melanoma: Results of a Randomized Phase III Study Comparing Temozolomide with Dacarbazine. Cancer Investigation, 2003, 21, 821-829.	1.3	49
118	Cancer of the Colon and Rectum. , 0, , 325-373.		0